Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2020 Earnings Conference Call - Final Transcript
Aug 04, 2020 • 04:30 pm ET
Thank you. We will now be conducting a question-and-answer session. [Operator Instructions] Our first question today comes from Eun Yang of Jefferies. Please proceed with your question.
This is Nalin [Phonetic] on for Eun. Just a couple of questions, particularly on the COVID-19 pneumonia questions -- on COVID-19 trial. Could you give us some details on what the pathway for getting an approval to non-COVID-19 pneumonia might look like? Following running a trial in COVID-19 pneumonia, which type of trial would you have to run? Which patient populations might be recruited? And how big might the trial be? Thank you.
Raul R. Rodriguez
Thank you, Nalin. I'll make a couple of comments and ask Wolfgang to also add other comments. So we are very interested in pneumonia and ARDS prevention some time ago and that publication that Wolfgang shared, published in 2019 before this COVID pandemic came upon us.
And so, it's an area where we thought that our product could have real potential. And broadly speaking, because there are several different key sources of pneumonias, viral, non-viral, bacterial, others, autoimmune, for example. So there's several different pockets of those. We think there's a great opportunity for our product to meaningfully contribute to stop that progression. And as I mentioned, I think, this is an annual ongoing issue that we could have a tremendous opportunity to benefit patients.
Exactly -- there's nothing approved in this area. So there isn't a playbook that's readily written that we could simply copy, but we may have to look at other proximate models for such a circumstance. And, B, work with the FDA closely in order for us to pursue that. I think, the COVID pneumonia experience will be very helpful, because it has the same mechanism as some of these others and so that might itself needing a very useful precedence for how we go about it. Wolfgang?
Thank you very much.
Wolfgang Dummer, M.D., Ph.D.
No. Go ahead.
Wolfgang Dummer, M.D., Ph.D.
We have one second delay. So I support what Raul is saying, obviously, our first step would be to generate solid data in COVID-19. Then, as always, depending on how large the effect size is, you can take your learnings onto the design of non-COVID ARDS trial. So in other words the larger the effect is, the smaller the potential trial needed. So, at this point probably a little bit too premature to determine what the sample size what that trial would look like.
Thank you, very much. Just one more question if I may. So the quarter for Dean. So you previously mentioned that the funding for the COVID-19 trial would come out of funding intended for further work on TAVALISSE. Could you please clarify, if there were other indications beyond ITP and wAIHA that the company had intended to explore? Thank you, very much.
Dean Schorno, C.P.A.
Yes. So, let me start and then I'll ask Raul to wrap up the comments on this with any incremental thoughts. But what we've described always is that we have exclusivity with fostamatinib/TAVALISSE through into